Back to Authors

Abbattista, Antonello

A5055636076 | I4210142120

Mayo Clinic

Pfizer Global Product Development-Oncology, Milan, Italy

Citations 1

SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAF V600E-mutant mCRC

Future Oncology | October 10, 2023 | Volume: 20 | Issue: 11 | Pages: 653-663

10.2217/fon-2022-1249 | PMID 37815847